132 related articles for article (PubMed ID: 33030093)
1. Is ramucirumab still the only second-line treatment in metastatic gastric cancer?
El Gharib K; Kourie HR
Pharmacogenomics; 2020 Nov; 21(17):1203-1206. PubMed ID: 33030093
[No Abstract] [Full Text] [Related]
2. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
3. Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature.
Takada J; Araki H; Ozawa N; Sugiyama T; Kubota M; Ibuka T; Shimizu M
J Gastrointest Cancer; 2019 Sep; 50(3):556-559. PubMed ID: 29250745
[No Abstract] [Full Text] [Related]
4. Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients.
Kim J; Byeon S; Kim H; Yeo JH; Hong JY; Lee J; Lim HY; Kang WK; Kim ST
Target Oncol; 2020 Apr; 15(2):203-209. PubMed ID: 32314267
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in HER2-positive metastatic gastric cancer: profile report.
Croxtall JD; McKeage K
BioDrugs; 2011 Aug; 25(4):257-9. PubMed ID: 21815701
[No Abstract] [Full Text] [Related]
6. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer.
Sorokin M; Poddubskaya E; Baranova M; Glusker A; Kogoniya L; Markarova E; Allina D; Suntsova M; Tkachev V; Garazha A; Sekacheva M; Buzdin A
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32060041
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Khan U; Shah MA
Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
[No Abstract] [Full Text] [Related]
9. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab and its use in gastric cancer treatment.
Bronte G; Galvano A; Cicero G; Passiglia F; Rolfo C; Bazan V; Russo A
Drugs Today (Barc); 2014 Sep; 50(9):613-21. PubMed ID: 25313368
[TBL] [Abstract][Full Text] [Related]
12. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
Kawai S; Fukuda N; Yamamoto S; Mitani S; Omae K; Wakatsuki T; Kato K; Kadowaki S; Takahari D; Boku N; Muro K; Machida N
BMC Cancer; 2020 Apr; 20(1):338. PubMed ID: 32316940
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab: a novel antiangiogenic agent.
Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab for gastric cancer.
Shitara K; Ohtsu A
Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
[TBL] [Abstract][Full Text] [Related]
16. [Ramucirumab - a new anticancer agent].
Telekes A; Deme D
Orv Hetil; 2016 Oct; 157(40):1587-1594. PubMed ID: 27690622
[TBL] [Abstract][Full Text] [Related]
17. Comment on Gu et al. entitled "Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis".
Li J; Jing J
Tumour Biol; 2014 Jul; 35(7):6177. PubMed ID: 24664586
[No Abstract] [Full Text] [Related]
18. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gumusay O; Benekli M; Ekinci O; Baykara M; Ozet A; Coskun U; Demirci U; Uner A; Dursun A; Atak EY; Buyukberber S
Jpn J Clin Oncol; 2015 May; 45(5):416-21. PubMed ID: 25732909
[TBL] [Abstract][Full Text] [Related]
19. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
20. [Molecular target for Her2 positive gastric cancer].
Boku N
Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2014-20. PubMed ID: 23221049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
